For the second time in two months, Celcuity Inc. failed to generate investor excitement despite disclosing positive news, ...

The prophylaxis of bleeding disorders usually requires frequent intravenous infusions that result in excessive treatment burden and residual bleeding risk. TGM-148 is a siRNA developed by Tangram ...

Newronika SpA received CE mark certification for its latest adaptive deep brain stimulation (aDBS) system, which includes the integration of Webbiobank, its proprietary cloud-based neural data ...

Another day, another two multibillion-dollar deals with Asian companies, this time involving Dizal Pharmaceutical Co. Ltd.

The Oxford Vaccine Group has delivered on its promise, and after starting work in mid-May has completed preclinical testing and is ready to begin a phase I trial of a vaccine against the Bundibugyo ...

Clinical updates for biopharma and med tech, including data readouts and publications: AB Science, Alkermes, Ani, CEPI, Eisai, GSK, Hemab, Immutep, Incyte, Ipsen, Lighthouse, Longeveron, Novo Nordisk, ...

South Korea is moving ahead with its biggest reform of drug review and pricing in more than a decade, reflecting a wider ...

For decades, treatment options for osteoarthritis have followed a familiar path: As cartilage deteriorates and pain worsens, ...

Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive eating behaviors. No effective ...

Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via ...

Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China.

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: C2N, Moderna, Pegbio, Precisio Biotix, Rani, Roche, Tibaray, Xvivo.